Interview: Living a Full and Filling Life with Late-Onset Tay-Sachs (LOTS) Pt. 2
Stewart and Lorrie Altman

Interview: Living a Full and Filling Life with Late-Onset Tay-Sachs (LOTS) Pt. 2

In Part 1 of our interview with Lorrie and Stewart Altman, we discussed the journey to the Late-onset Tay-Sachs disease (LOTS) diagnosis, how Lorrie and Stewart's outlook shaped their lives,…

Continue Reading Interview: Living a Full and Filling Life with Late-Onset Tay-Sachs (LOTS) Pt. 2
First CAR T-Cell Therapy for Multiple Myeloma Cleared for Use in Japan
source: pixabay.com

First CAR T-Cell Therapy for Multiple Myeloma Cleared for Use in Japan

According to a press release from the pharmaceutical company Bristol Myers Squibb, the company's CAR T-Cell therapy idecabtagene vicleucel (marketed as Abecma) has been approved by the Japanese Ministry of…

Continue Reading First CAR T-Cell Therapy for Multiple Myeloma Cleared for Use in Japan
New Collaboration to Evaluate Nirogacestat in Combination with ABBV-383 in Relapsed or Refractory Multiple Myeloma
https://unsplash.com/photos/tV-RX0beDp8

New Collaboration to Evaluate Nirogacestat in Combination with ABBV-383 in Relapsed or Refractory Multiple Myeloma

In a recent news release, biopharmaceutical companies AbbVie, Inc. and SpringWorks Therapeutics, Inc. ("SpringWorks") shared that the two had entered into a joint clinical trial collaboration agreement. Through this collaboration,…

Continue Reading New Collaboration to Evaluate Nirogacestat in Combination with ABBV-383 in Relapsed or Refractory Multiple Myeloma
Older Multiple Myeloma Patients Shouldn’t be Denied Transplants Solely Based on Age
source: pixabay.com

Older Multiple Myeloma Patients Shouldn’t be Denied Transplants Solely Based on Age

Many doctors have thought in the past that age should be an automatic ineligibility factor for multiple myeloma patient transplants. However, Dr. Langren, Dr. Gasparetto, Dr. Landgren, Dr. Hofmeister, and…

Continue Reading Older Multiple Myeloma Patients Shouldn’t be Denied Transplants Solely Based on Age
Abecma for MM Approved by European Commission
source: pixabay.com

Abecma for MM Approved by European Commission

According to Pharmaceutical Business Review, Abecma (idecabtagene vicleucel), a CAR T-cell therapy designed to treat patients with relapsed and refractory (R/R) multiple myeloma (MM), received conditional marketing authorization from the…

Continue Reading Abecma for MM Approved by European Commission

GENESIS Trial: Almost Ninety Percent of Multiple Myeloma Patients Were Able to Proceed to Transplantation

A recent article in Cancer Network announced that motixafortide met its primary endpoint in the GENESIS trial for multiple myeloma patients who were scheduled for stem cell transplantation. Often, the…

Continue Reading GENESIS Trial: Almost Ninety Percent of Multiple Myeloma Patients Were Able to Proceed to Transplantation